Integrated SWIFT-1/2 enrolled 762 patients with type 2 asthma; depemokimab 100 mg SC q26 weeks achieved clinically meaningful exacerbation reductions versus placebo. Comorbid CRSwNP predicted greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results